Meridian Bioscience Announces Anticipated Closing Date of the Pending Merger
CINCINNATI, Dec. 12, 2022 /PRNewswire/ — Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, announced that it has entered into a side letter with the buyer, setting the closing date of Meridian’s pending merger for January 31, 2023. As previously disclosed, on July 7, 2022, […]
MERIDIAN BIOSCIENCE REPORTS FOURTH QUARTER AND FULL YEAR FISCAL 2022 OPERATING RESULTS
CINCINNATI, Nov. 22, 2022 /PRNewswire/ — Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced financial results for the fourth quarter and fiscal year ended September 30, 2022. Fourth Quarter 2022 Highlights (Comparison to Fourth Quarter Fiscal 2021): Consolidated net revenues totaled $65.7 million, a decrease of 14% year-over-year Diagnostics segment net revenues increased 14% year-over-year to […]
MERIDIAN BIOSCIENCE REPORTS THIRD QUARTER FISCAL 2022 OPERATING RESULTS
CINCINNATI, Aug. 5, 2022 /PRNewswire/ — Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced financial results for the third quarter ended June 30, 2022. Third Quarter Fiscal 2022 Highlights (Comparison to Third Quarter Fiscal 2021): Consolidated net revenues totaled $67.8 million, an increase of 7% year-over-year Diagnostics segment net revenues increased 36% year-over-year to a record $42.4 million Life Science segment delivered […]
Meridian Bioscience Receives Re-Authorization from FDA for its Revogene® SARS-CoV-2 Molecular Assay
CINCINNATI, July 29, 2022 /PRNewswire/ — Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, announced that it received re-authorization of its Emergency Use Authorization (EUA) for the Revogene® SARS-COV-2 molecular assay from the U.S. Food and Drug Administration (FDA). Meridian expects to begin shipping this product before the end […]
Meridian Bioscience, Inc. Enters into Agreement to Be Acquired by SD Biosensor and SJL Partners in $1.53 Billion All-Cash Transaction
Shareholders to Receive $34.00 Per Share in Cash, Providing Immediate, Compelling and Certain Value Transaction Follows Deliberate Review, Including Outreach to Potential Strategic and Financial Partners CINCINNATI and SEOUL, South Korea, July 7, 2022 /PRNewswire/ — Meridian Bioscience, Inc. (“Meridian” or the “Company”) (NASDAQ: VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, and SD Biosensor, Inc. […]
Meridian Bioscience Announces Preliminary Results for Fiscal 2022 Third Quarter
CINCINNATI, July 7, 2022 /PRNewswire/ — Meridian Bioscience, Inc. (“Meridian” or the “Company”) (NASDAQ: VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, today provided preliminary results for its third quarter of fiscal 2022. For the third quarter of fiscal 2022, preliminary unaudited net revenues are expected to be between $66 million and $69 million. The […]
Meridian Launches New qPCR Master Mixes for Stool Samples to Accelerate Development of Molecular Assays
CINCINNATI, June 20, 2022 /PRNewswire/ — Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, announced today two new sample-specific master mixes, Lyo-Ready Direct DNA qPCR Stool Mix, and Lyo-Ready Direct RNA/DNA qPCR Stool Mix. These innovative master mixes improve the molecular detection of DNA and RNA from crude fecal specimens while […]
Meridian Bioscience Launches Lyo-Ready qPCR Inhibitor Tolerant Blood-Specific Master Mixes for DNA & RNA Direct Detection
CINCINNATI, March 29, 2022 /PRNewswire/ — Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, announced today the launch of two new master mixes that detect DNA and RNA in crude blood samples down to a single copy – enabling the earliest detection of cancer using non-invasive liquid biopsy. […]
Meridian Bioscience responds to the Monkeypox Outbreak with its Inhibitor-Tolerant qPCR Master Mixes for the Development of Molecular Tests
CINCINNATI, May 26, 2022 /PRNewswire/ — Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, announced today that its inhibitor-tolerant qPCR master mixes are ideal for the development of fast, accurate and highly sensitive qPCR monkeypox virus (monkeypox) molecular diagnostic tests. The recent outbreak of monkeypox has caused global […]
Meridian Bioscience to Participate in the 2022 H.C. Wainwright Global Investment Conference
CINCINNATI, May 23, 2022 /PRNewswire/ — Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, announced today its participation in the 2022 H.C. Wainwright Global Investment Conference. Jack Kenny, Chief Executive Officer, will pre-record the company’s presentation. A link to Mr. Kenny’s presentation will be posted on May 24, 2022, on the Meridian […]